ISPOR 2022 - Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research
May 15 - May 18, 2022 | National HarborMDUS
LARVOL is not affiliated with Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research and all trademarks, logos, and brand names are property of their respective owners
Showing 107 abstracts linked to Trials
Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib
Matching-Adjusted Indirect Comparison of Amivantamab Vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States
US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada
Post-Infusion Monitoring Costs By Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Who Received Second-LINE Treatment with Lisocabtagene Maraleucel (LISO-CEL) in the Transform Study: A United States Subgr ...
Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients
Reproduction of Control Groups in Two Global RCTs of Anti-Cancer Drugs Using Health Insurance Claims Data in Japan
Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma
Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma
Comparative Efficacy and Safety of Ozanimod and Ponesimod for Relapsing Multiple Sclerosis: A Matching-Adjusted Indirect Comparison
Randomized Clinical Trial Replication for Cardiovascular Outcomes of EMPA-Reg Trial: Retrospective Cohort Study
Health and Economic Outcomes of Botulinum Toxin-a Products for Adult Patients with UPPER LIMB Spasticity in a Real-World Setting
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Vs. Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Non-Squamous, Advanced Non-Small Cell Lung Cancer in the USA